The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
They must have a pretty good idea of what the results will be like. I can’t see them presenting at a shares magazine webinar if they were going to be bad. Okay, you have to tell the truth, but you don’t have to rub it in - and embarrass yourselves more than necessary.
Thoughts are I've topped up by 50%.
Having taken profits at 5p and 10p on the way up, this has been a great share for me. Now it's been a long long fall due to what I see as temporary disruptions. The long term drivers are stronger than ever with the absolute necessity of environmental stewardship finally coming to the fore as climate change undeniably bites. The longer Covid rages and takes lives the more deeply people are realising things have to change. This is one way. I wonder if I should have doubled rather than a measly 50%.... Grief.
Yesterday Swiss solar panels (MBTN), today ITX.
Investors Chronicle runs regular screens, and this is for top quality AIM/small cap shares. Cerillion was one of just 5 that have passed this year, and there is a long write up just on Cerillion.
Copying this with slight practical alterations from what Rivaldo posted on MWE [because I'm lazy! - plus he is far and away more knowledgeable than I am]:
"To summarise for non-subscribers, Algy Hall has run a screen covering the entire FTSE small cap index and AIM to find which companies pass all the stringent tests below to qualify as a "High Quality" share.
Only 5 companies passed. CER are one of them (RNWH and MWE, which I also hold, are others):
Https://www.investorschronicle.co.uk/ideas/2021/08/26/5-high-quality-aim-shares/
"The full screening criteria:
PE ratio above bottom fifth and below top fifth of all stocks screened.
A genuine value (GV) ratio below the top quarter of stocks screened.
GV ratio = (enterprise value/operating profit)/(forecast EPS growth + dividend
yield)
Earnings growth forecast in each of the next two financial years.
Interest cover of five times or more.
Positive free cash flow.
Market capitalisation over £20m.
A top-quarter return on equity (RoE) in each of the past three years.
A top-quarter operating margin in each of the past three years.
Operating profit growth over the past three years"
Astonishing that such a quality company, with such an sp record, has such a small following here.
Wanted to watch your Channel 4 documentary JoeyDiamond:
"Video unavailable
This video contains content from Channel 4, who has blocked it in your country on copyright grounds."
Surprise, surprise.
Post 2, from Zeus, is useful. Wonder where they are getting the extra info from.
I have a friend who interprets for doctors by telephone, internationally as well as here in the UK. She says that the Americans have much longer appointments, up to an hour (not our 2 minutes!), and they go all round the houses and are very thorough. Since time is money and those 1 hour appointments must cost, and they must show thoroughness, I would expect US sales to expand much faster than our skinflint NHS ones.
I would guess as the other tests are validated they could all be done with the one blood sample. Great if they can especially highlight the more occult ones, such as pancreas, oesophageal, etc.
Agreed, Trek, this "proves the engine works". We have the horse, a great big Suffolk Punch Shire.... now for the cart. As the results become more and more conclusive hopefully we'll get the contracts to suit. How much excuse for waiting now?
https://www.medrxiv.org/content/10.1101/2021.08.17.21262105v1
"Earlier detection of lung cancer is possible, but difficult and costly to achieve. Screening with Low Dose Computed Tomography (LDCT)scanning has been shown to reduce mortality by 20-25% over the past decade but uptake amongst those most likely to suffer the disease has been slow. Resource constraints and a high false positive rate have also limited adoption of LDCT in many health systems. Targeted screening of people most likely to benefit using a range of biomarkers may be one way to improve the yield and reduce the resource requirements of LDCT. Autoantibodies, which amplify the signal produced by cancer derived proteins, are present in the blood of people mounting an immune response to cancer are a potential way to select those at highest risk. We have followed up 12 208 people enrolled in the ECLS trial for three years and shown that the specificity for early stage (I &II) disease is 90.3% throughout that period. More cancers were detected in the control than the intervention arm of the trial (101V 83). Sensitivity was 77.8% after 6 months and dropped to 46.4% after 3 years. At the end of three years the hazard ratios (95%CI) for All Cause, Cancer Specific and Lung Cancer Mortality was 0.82(0.67-1.01), 0.72(0.54-0.97) and 0.70(0.46-1.08) respectively for those randomised to Early CDT testing. As a range of treatment modalities become increasingly more effective it is even more important to target LDCT on those most likely to have early stage disease. Autoantibody testing may be one method of targeting early detection on those most likely to benefit."
I can't say I understand all this! For example, "More cancers were detected in the control than the intervention arm of the trial (101V 83)." I assume they weren't just letting any diagnosed cancers in any patient be left untreated so exactly what were the 'control' and 'intervention' arms?! Maybe control had LDCT, but not the Early CDT testing. Implies that LDCT is better: but it's expensive, with a high rate of false positives, and has low take up. Whereas a simple blood test the GP can almost sneak in, with 90.3% specifity...... is easy and great.
But if anyone can explain this better to laymen, please do.
Ditto. Clearly it's an awful day for the market. If people are scared it's the start of a crash and they see this start to fall they'll sell anyway. "There must be a reason...."
But I wonder if it is the outlook as well: they had a huge Covid boost and hit such a high a year ago, but like VLG are being hit by overstocking (and new competitors) which has to be worked through. BUT.... they say it is stabilising now, and medium to long term is great. Especially like the licence income.
"Outlook and current trading
The sanitiser market has experienced a period of unprecedented activity as a result of COVID-19, resulting in record financial performance for Byotrol. We believe the increase in anti-microbial awareness and mass-uptake of related products will continue long into the future.
Management remains extremely positive on the medium to long-term outlook where the market is forecast to grow globally at 8 to 10% per year from pre-COVID levels and industry earnings growth is likely to exceed this as weaker competitors with inferior chemistries, and those that lack regulatory approval, fall away.
In the short-term, revenue from product sales in the new financial year to date has been hindered by closed venues from extended lockdowns, new competition, and an excess of inventory. However, the market does now appear to be stabilising and management now expect product sales for FY22 at a level some 10 to 20% below those for FY21: an exceptional year which was itself over 90% ahead of FY20."
And they are in profit, no debt, and you can hardly say this whopping result was priced in. May top up, when it looks like it's stabilised. You could hardly this coming year to have sales like the last: 10-20% below seems pretty good to me, seeing it's so much up on the year before. Seems likely to me that many buyers have discovered their virtues and they expect will stay with them.
"Vaccine, sir?..... No?......Then can I interest you in some mouthwash?" :)
RNS 16th November 2020: "In their published in-vitro[2] study, scientists at Cardiff University concluded that Venture Life's two CPC based mouthwashes eradicated the SARS-CoV-2 (COVID-19) virus completely (>5log reduction, equivalent to 99.999%) within a 30 second exposure."
Further to my thoughts yesterday re the pending results for the in vivo trial for Covid killing...
I can see why, say, a drug might behave differently inside the body to outside it, but I really can't see why a mouthwash that kills Covid so effectively in a test tube would not kill it probably just as effectively in the mouth and throat. It's just a different surface, but it's the same bug. Maybe some factor I can't think of would knock it down by a few percent, but to knock it out completely??!! No.
And remember this: "Cardiff University went on to state that the 'exact formulation is also important'. Whilst the CPC technology in Venture Life's mouthwash proved highly effective in the in-vitro study, they also tested a third mouthwash, which also contained both CPC and another ingredient, yet this proved ineffective. Their conclusion was that active ingredients in mouthwashes were not, on their own, enough to rely on, but rather it was the construct of the mouthwash formulations that was the critical determinant of a successful outcome." The 'construct' of Dentyl's formulation may not be easy or legal to copy.
So it's very likely we have a unique mouthwash already widely on sale in many countries that is (a) cheap (b) effectively kills Covid-19 at the initial site of infection (c) doesn't need to be transported and stored at -80 deg C! (d) We can easily distribute to most of the world - check out the map:
https://www.venture-life.com/our-partners/
Happy! :)))
Topped up.
You guys are among those I look up to as knowing what you're talking about (!), and if the Dentyl results they mention ["The clinical study at Cardiff University on our mouthwashes completed in April 2021 and the results have been submitted for peer review in key journals. We are hopeful to see the publication of these results very soon."] come through well it could be massive, as per last November's RNS on in vitro trials: https://www.lse.co.uk/rns/VLG/results-of-in-vitro-clinical-trial-published-ham8hx1frl4du16.html
Mouthwash won't cure Covid in the lung, but at the beginning of the pandemic it seemed that it takes hold in the throat, then moves to the lung. Even if the effect was not 100% in vivo it's a cheap available mouthwash that hopefully slows down the bug long enough for the body to clear for action and rig the boarding nets...
It is however taking a long time to be peer reviewed, from April to now, which would be very sad indeed if it really is effective. But if not I don't think the downside would be too large. Dentyl's had no mention in the public sphere.
... my holding. My buy 12.628p was marked as a sell, so all of those others at that price are probably buys.
Couldn't believe that it was down after those results.
Sometimes my very best buys are with companies I'm well down on after a long fall and top up in the dumps. The more negative the board the better - it's hard when you've been in a long time and it just never returns. Peoples, you're not negative enough! Twix, keep at it! Please! [Actually, no, you can stop now :) - I've bought.] I'm no expert, but it seems to me it takes time to change downward momentum even when it all starts going well. Good news at those times is like water off a duck's back, it does nothing. It's a great moment if you can get it. Time will tell if this was it...
2:30 into that CEO and CFO broadcast someone gave a link to earlier: "we've taken the margin up to 62%". Nice.
https://www.brrmedia.co.uk/broadcasts-embed/611281d38f5b0057e031384d/yourgene-health-full-year-results-update/?popup=true
Agreed, that’s a really useful RMS.
Does anyone know how the costs compare with the standard antibody based method of collecting CTCs?
If they compare well it’s hard to see any reason why we should not become the standard method of collection worldwide.
Apologies if this has already been discussed in depth, I've had an eye open but among the thousands of posts it would be easy to miss.
Simply that with Deep Mind releasing protein shapes to all if I understand Affimers right Avacta may be in the best place to take advantage of a stunning new tech, with the set-up and IP already in place to be able to produce affimers to fit and lock into many unique protein folded shapes, and Deep Mind's willingness to quickly process a DNA sequence to produce a likely shape.. Maybe there are alternative technologies, I don't know, but I wonder if this will open up enormous new opportunities to Avacta.
Is someone techy able to confirm or deny this? Thanks.
Odd sequences of numbers on the sells. I know nothing about these things but I suspect an institution has been taking profits. More fool them as far as I'm concerned, but I suppose they have to, to maintain a balance, while we can choose to chance it. But IMO yesterday's news was very good. Maybe they do it at a time like this so the large amounts don't start a downward slide and destroy the value of the rest of their holding. MPAC was 48p less than 5 years ago.
Just wild ignorant guessing.